摘要
目的观察晚期肝癌患者行自体CIK细胞及树突状细胞联合索拉非尼治疗的临床疗效及不良反应。方法采用患者自体外周血进行细胞因子诱导的杀伤细胞(cytokine induced killer,CIK)及树突状细胞(dendritic cell,DC)扩增,并应用流式细胞术检测其CIK、DC-CIK表型,然后采取静脉回输方法,对原发性肝癌进行自体的CIK细胞及DC细胞联合索拉非尼治疗。结果索拉非尼联合1个疗程DC-CIK治疗后CR 0例,PR 15例,MR 22例,SD 5例,PD 2例,总缓解(CR+PR+MR)率为84.1%。患者免疫功能提高,生活质量改善。结论自体CIK细胞及树突状细胞联合索拉非尼治疗晚期肝癌患者疗效尚可,不良反应可耐受。
Objective To analyze the clinical efficacy and side effects in patients with advanced hepatic cancer treated with Sorafenib and autologous CIK and CD.Methods Cytokine-induced killer cells（cytokine induced killer,CIK） and dendritic cells（Dendritic Cell,DC） from the peripheral blood of the patients with advanced hepatocellular carcinoma were amplified.The amplified CIK and DC-CIK were transfused back,and Sorafenib was given to the patients,after the phenotype of CIK and DC-CIK was tested by using the flow cytometry.Results After one course of treatment,0 of the 44 patients had CR,and 15,22,5,and 2 of the 44 patients had PR,MR,SD,and PD disease,with a total remission rate（CR＋PR＋MR） of 84.1%.Sorafenib and autologous transfusion of CIK and CD improved the immune function and quality of life.Conclusion Autologous CIK and DC transfusion combined with Sorafenib may have good efficacy with accepted toxicities.
出处
《实用癌症杂志》
2011年第5期459-461,共3页
The Practical Journal of Cancer
关键词
晚期肝癌
索拉非尼
CIK细胞
DC细胞
过继免疫疗法
Advanced hepatocellular carcinoma
Sorafeni
CIK cells
DC cells
Adoptive immunotherapy
